進行性尿路上皮がんおよび選択された線維芽細胞増殖因子受容体(FGFR)遺伝子異常を有する参加者におけるビンフルニンまたはドセタキセルまたはペンブロリズマブと比較したエルダフィチニブの研究 (THOR)
進行性尿路上皮がんおよび選択された FGFR 遺伝子異常を有する被験者におけるビンフルニンまたはドセタキセルまたはペムブロリズマブと比較したエルダフィチニブの第 3 相試験
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-[L]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
A study of erdafitinib versus standard of care, consisting of chemotherapy (docetaxel or vinflunine) or anti-PD-(L) 1 agent pembrolizumab, in participants with advanced urothelial cancer and selected FGFR aberrations who have progressed on or after 1 or 2 prior treatments, at least 1 of which includes an anti-PD-(L) 1 agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2). It will consist of screening, treatment phase (from randomization until disease progression, intolerable toxicity, withdrawal of consent or decision by investigator to discontinue treatment, post-treatment follow-up (from end-of-treatment to participants death, withdraws consent, lost to follow-up study completion for the respective cohort, whichever comes first). The study will have long term extension (LTE) period after clinical cutoff date is achieved for final analysis of each cohort and participants eligible in the opinion of the investigator, will continue to benefit from the study intervention. Efficacy, pharmacokinetics, biomarkers, patient reported outcomes, medical resource utilization and safety will be assessed.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 3
アクセスの拡大
アクセスの拡大
承認済み
- 利用可能: 現在、この治験治療には拡張アクセスが利用可能であり、臨床研究の参加者ではない患者が医薬品、生物学的製剤、または医療機器にアクセスできる可能性があります
- 利用不可: 以前はこの介入に対して拡張アクセスが利用できましたが、現在は利用できず、将来も利用できなくなります。
- 一時的に利用不可: 現在、この介入では拡張アクセスを利用できませんが、将来利用できるようになる予定です。
- マーケティング承認済み: 介入は、米国食品医薬品局によって一般使用が承認されています。
連絡先と場所
研究場所
-
-
Alaska
-
Anchorage、Alaska、アメリカ、99503
- Alaska Urological Institute dba Alaska Clinical Research Center
-
-
California
-
Sacramento、California、アメリカ、95817
- University of Calif Davis Medical Center
-
St. Helena、California、アメリカ、94574
- St. Helena Hospital - Martin-O'Neil Cancer Center
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Miami、Florida、アメリカ、33136
- University of Miami Sylvester Cancer Center
-
Orange、Florida、アメリカ、32763
- Mid Florida Hematology Oncology
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30318-0922
- Piedmont Cancer Institute
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- Rush University
-
Hines、Illinois、アメリカ、60141
- Edward Hines Jr V A Hospital
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40207
- Norton Cancer Institute
-
-
Maryland
-
Lanham、Maryland、アメリカ、20706
- Maryland Oncology Hematology, PA
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109-5000
- University of Michigan Health System
-
-
Nevada
-
Reno、Nevada、アメリカ、89509
- VA Sierra Nevada Health Care System
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- Dartmouth Hitchcock Medical Center
-
-
New York
-
New York、New York、アメリカ、10029
- Weill Cornell Medical College
-
The Bronx、New York、アメリカ、10461
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- Levine Cancer Institute, Carolinas HealthCare System
-
Salisbury、North Carolina、アメリカ、28144
- W G Bill Hefner VA Medical Center
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45242
- Oncology Hematology Care
-
-
Texas
-
Fort Worth、Texas、アメリカ、76104
- The Center for Cancer and Blood Disorders
-
Houston、Texas、アメリカ、77030
- MD Anderson Cancer Center
-
Houston、Texas、アメリカ、77024
- Texas Oncology-Memorial City
-
Tyler、Texas、アメリカ、75702
- Texas Oncology Tyler
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- INOVA Dwiight &Martha Schar Cancer Institute
-
Norfolk、Virginia、アメリカ、23502
- Virginia Oncology Associates
-
-
Washington
-
Seattle、Washington、アメリカ、98108
- VA Puget Sound Healthcare System
-
-
-
-
-
Buenos Aires、アルゼンチン、C1426AGE
- Centro Oncológico Korben
-
Buenos Aires、アルゼンチン、C1419AHN
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
Buenos Aires、アルゼンチン、C1431FWN
- CEMIC Saavedra
-
Córdoba、アルゼンチン、X5000KPH
- Centro Urologico Profesor Bengio
-
Córdoba、アルゼンチン、C5000
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Mar del Plata、アルゼンチン、B7602CBM
- Hospital Privado de Comunidad
-
Pergamino、アルゼンチン、B2700CPM
- Centro de Investigacion Pergamino SA
-
Viedma、アルゼンチン、R8500ACE
- Clínica Viedma
-
-
-
-
-
Bristol、イギリス、BS2 8ED
- University Hospitals Bristol - Bristol Haematology & Oncolog
-
London、イギリス、W1G 6AD
- Sarah Cannon Research Institute
-
London、イギリス、W6 8RF
- Charing Cross Hospital
-
London、イギリス、EC1A 7BE
- St Bartholomew's Hospital
-
Manchester、イギリス、M20 4BX
- The Christie NHS Foundation Trust Christie Hospital
-
Plymouth、イギリス、PL6 8QH
- Derriford Hospital-Department of Medical Oncology
-
Sheffield、イギリス、S10 2 RX
- University of Sheffield
-
Southampton、イギリス、SO16 6YD
- Southampton General Hospital
-
Sutton、イギリス、SM2 5NG
- Royal Marsden Hospital
-
-
-
-
-
Haifa、イスラエル、31096
- Rambam Health Care Campus
-
Jerusalem、イスラエル、91120
- Hadassah Medical Center
-
Kfar Saba、イスラエル、44281
- Meir Medical Center
-
Petach Tikvah、イスラエル、49100
- Rabin Medical Center, Beilinson Hospital
-
Tel Aviv、イスラエル、64239
- Sourasky Medical Center
-
Tel HaShomer、イスラエル、52621
- The Chaim Sheba Medical Center
-
Tzrifin、イスラエル、70300
- Assaf Harofeh Medical Center
-
-
-
-
-
Alessandria、イタリア、15121
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo Alessandria
-
Arezzo、イタリア、52100
- Ospedale S. Donato - Asl 8 Arezzo
-
Aviano、イタリア、33081
- CRO IRCCS Istituto Nazionale Tumori
-
Bergamo、イタリア、24127
- Azienda Ospedaliera Papa Giovanni XXIII
-
Brescia、イタリア、25123
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
-
Cremona、イタリア、26100
- Istituti Ospitalieri di Cremona, AO di Cremona
-
Florence、イタリア、50139
- Oncologia Medica
-
Genova、イタリア
- SPDC Villa Scassi
-
Meldola、イタリア、47014
- IRST Meldola Forli
-
Milan、イタリア、20132
- IRCCS Ospedale San Raffaele
-
Milan、イタリア、20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan、イタリア、20141
- European Institute of Oncology
-
Modena、イタリア、41124
- AOU Policlinico di Modena
-
Naples、イタリア、80131
- IRCCS-Fondazione Pascale
-
Novara、イタリア、28100
- Ospedale Maggiore della Carita
-
Orbassano、イタリア、10043
- Aou San Luigi Gonzaga
-
Padova、イタリア、35128
- Istituto Oncologico Veneto Iov Irccs Padova
-
Parma、イタリア、43126
- AOU di Parma
-
Pavia、イタリア、27100
- IRCCS Policlinico San Matteo
-
Pavia、イタリア、27100
- Ist. Clinici Scientifici Maugeri - Unità Operativa di Oncolo
-
Pisa、イタリア、56126
- Azienda Ospedaliero Universitaria Pisana
-
Poggibonsi (SI)、イタリア、53100
- Usl 7 Siena - Ospedale Alta Valdelsa ASL TOSCANA SUD-EST
-
Province of Macerata、イタリア、62100
- UOC Oncologia Ospedale Provinciale di Macerata
-
Roma、イタリア、00168
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Siena、イタリア、53100
- Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte
-
Torino、イタリア、10123
- Oncologia Medica-Città Della Salute E Della Scienza Di Torino
-
Torrette Di Ancona、イタリア、60126
- Azienda Ospedaliero - Universitaria Ospedali Riuniti
-
-
-
-
-
Dnipro、ウクライナ、49102
- Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
-
Dnipro、ウクライナ、49100
- Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council
-
Dnipropetrovsk、ウクライナ、49005
- MI Dnipropetrovsk Region Clinical Hospital n a I.I.Mechnikov
-
Ivano-Frankivsk、ウクライナ、76008
- Ivano-Frankivsk Regional Clinical Hospital
-
Kharkiv、ウクライナ、61070
- Municipal non-profit enterprise 'Regional Center of Oncology'
-
Kharkiv、ウクライナ、61037
- Regional Medical Clinical Center for Urology and Nephrology named after V.I. Shapoval
-
Kyiv、ウクライナ、03022
- National Cancer Institute
-
Kyiv、ウクライナ、03115
- State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center
-
Lviv、ウクライナ、79010
- Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital'
-
Uzhhorod、ウクライナ、88000
- Transkarpathian Regional University Oncology Clinic
-
Vinnitsa、ウクライナ、21029
- Podilskiy Regional Center of Oncology
-
Zaporizhzhya、ウクライナ、69040
- Zaokod
-
Zaporizhzhya、ウクライナ、69600
- Zaporizhzhia medical Academy of postgraduate education, Zaporizhzhia Regoinal Clinical Hospital
-
-
-
-
-
Amsterdam、オランダ、1066 CX
- Antoni van Leeuwenhoek
-
Nieuwegein、オランダ、3430 EM
- St. Antonius Ziekenhuis Nieuwegein
-
The Hague、オランダ、2545 CH
- Haga ziekenhuis
-
-
-
-
-
Camperdown、オーストラリア、2050
- Chris O'Brien Lifehouse
-
Frankston、オーストラリア、3199
- Peninsula & South Eastern Haematology and Oncology Group
-
Kogarah、オーストラリア、2217
- St George Hospital
-
Melbourne、オーストラリア、3000
- Peter MacCallum Cancer Centre
-
Melbourne、オーストラリア、3199
- Frankston Hospital
-
Murdoch、オーストラリア、6150
- Fiona Stanley Hospital
-
-
-
-
-
Graz、オーストリア、8036
- LKH-Univ. Klinikum Graz
-
Linz、オーストリア、4020
- Ordensklinikum Linz GmbH Elisabethinen
-
Salzburg、オーストリア、5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna、オーストリア、1020
- Krankenhaus der Barmherzigen Brüder
-
Vienna、オーストリア、A-1090
- Medical University Vienna MUV
-
-
-
-
British Columbia
-
Kelowna、British Columbia、カナダ、V1Y 5L3
- BC Cancer Agency - Southern Interior
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- Vancouver Cancer Centre
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3E 0V9
- Cancercare Manitoba
-
-
Ontario
-
Thunder Bay、Ontario、カナダ、P7B 6V4
- Thunder Bay Regional Health Sciences Centre
-
Toronto、Ontario、カナダ、M5G 2M9
- Princess Margaret Hospital- UHN
-
-
Saskatchewan
-
Regina、Saskatchewan、カナダ、S4T 7T1
- Saskatchewan Cancer Agency (SCA) - Allan Blair Cancer Centre
-
-
-
-
-
Athens、ギリシャ、15125
- Athens Medical Center
-
Athens、ギリシャ、11526
- Errikos Dunant Hospital Center
-
Athens、ギリシャ、15562
- Metropolitan General A E
-
Athens、ギリシャ、115 28
- University of Athens Medical School - Regional General Hospi
-
Larissa、ギリシャ、41110
- University Hospital Of Larissa
-
Pátrai、ギリシャ、26504
- University General Hospital of Rio Patras
-
Thessaloniki、ギリシャ、54645
- Euromedica General Clinic
-
Thessaloniki、ギリシャ、14564
- Interbalkan European Medical Center
-
Thessaloniki、ギリシャ、56403
- Papageorgiou General Hospital Of Thessaloniki
-
-
-
-
-
Badajoz、スペイン、06006
- Hosp. Univ. Infanta Cristina
-
Badalona、スペイン、08916
- Institut Català D'Oncologia-Hospital Universitari Germans Trias I Pujol
-
Barcelona、スペイン、08041
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona、スペイン、08036
- Hosp Clinic de Barcelona
-
Cáceres、スペイン、10003
- Hosp. San Pedro de Alcantara
-
Córdoba、スペイン、14004
- Hosp Reina Sofia
-
Granada、スペイン、18014
- Hosp. Univ. Virgen de Las Nieves
-
Jaén、スペイン、23007
- Complejo Hospitalario de Jaen
-
Las Palmas de Gran Canaria、スペイン、35016
- Hosp. Univ. Insular de Gran Canaria
-
Lugo、スペイン、27003
- Hosp. Univ. Lucus Augusti
-
Madrid、スペイン、28041
- Hosp. Univ. 12 de Octubre
-
Madrid、スペイン、28046
- Hosp. Univ. La Paz
-
Majadahonda、スペイン、28220
- Hosp. Univ. Pta. de Hierro Majadahonda
-
Manresa、スペイン、08243
- ALTHAIA, Xarxa Assistencial Universitària de Manresa
-
Pamplona、スペイン、31008
- Hosp. de Navarra
-
Seville、スペイン、41013
- Hosp. Virgen Del Rocio
-
Seville、スペイン、41009
- Hosp. Virgen Macarena
-
Valencia、スペイン、46014
- Hosp. Gral. Univ. Valencia
-
Valencia、スペイン、46026
- Hosp. Univ. I Politecni La Fe
-
Zaragoza、スペイン、50009
- Hosp. Univ. Miguel Servet
-
-
-
-
-
Adana、トルコ(Türkiye)、01120
- Baskent University Adana Practice and Research Center Kisla Health Campus
-
Ankara、トルコ(Türkiye)、6100
- Hacettepe University Medical Faculty
-
Istanbul、トルコ(Türkiye)、34098
- Istanbul Universitesi Cerrahpasa Tip Fakultesi
-
Istanbul、トルコ(Türkiye)、34147
- Bakirkoy Training and Research Hospital
-
Istanbul、トルコ(Türkiye)、34722
- T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
-
Istanbul、トルコ(Türkiye)、34214
- Medipol Mega University Hospital
-
Istanbul、トルコ(Türkiye)、34093
- Bezmialem University Medical Faculty
-
Istanbul、トルコ(Türkiye)、34890
- Pendik Training and Research Hospital
-
Izmir、トルコ(Türkiye)、35340
- Dokuz Eylul Universitesi Tip Fakultesi
-
Izmir、トルコ(Türkiye)、35100
- Ege University
-
Kocaeli、トルコ(Türkiye)
- Kocaeli University Medical Faculty
-
Malatya、トルコ(Türkiye)、44400
- Inonu Universitesi Turgut Ozal Tip Merkezi, Ic Hastaliklari
-
-
-
-
-
Berlin、ドイツ、10967
- Vivantes Klinikum Am Urban
-
Braunschweig、ドイツ、38126
- Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
-
Dresden、ドイツ、01307
- Universitatsklinikum Carl Gustav Carcus Dresden
-
Düsseldorf、ドイツ、40225
- Universitaetsklinikum Duesseldorf
-
Erlangen、ドイツ、91054
- Friedrich-Alexander Universitaet Urologische Universitaetskl
-
Frankfurt、ドイツ、60590
- Universitatsklinikum Frankfurt
-
Freiburg im Breisgau、ドイツ、79106
- Universitatsklinikum Freiburg
-
Greifswald、ドイツ、17475
- Universitätsmedizin Greifswald
-
Göttingen、ドイツ、37099
- Universitatsmedizin Gottingen
-
Hamburg、ドイツ、22763
- Asklepios Klinik Altona
-
Hanover、ドイツ、30625
- Medizinische Hochschule Hannover
-
Lübeck、ドイツ、23538
- Universitatsklinikum Schleswig Holstein Campus Lubeck
-
Mannheim、ドイツ、68167
- Medizinische Fakultät Mannheim der Universität Heidelberg
-
Münster、ドイツ、48149
- Universitaetsklinikum Muenster
-
Nürtingen、ドイツ、72622
- Studienpraxis Urologie Drs. Feyerabend
-
Regensburg、ドイツ、93053
- Caritas-Krankenhaus St. Josef
-
Rostock、ドイツ、18057
- Universitaetsmedizin Rostock
-
Velbert、ドイツ、42551
- MVZ-Onkologie Velbert GbR
-
Weiden、ドイツ、92637
- Kliniken Nordoberpfalz AG/Klinikum Weiden
-
-
-
-
-
Budapest、ハンガリー、1082
- Semmelweis Egyetem
-
Budapest、ハンガリー、1122
- Országos Onkológiai Intézet, Urogenitális Tumorok és Klinikai Farmakológiai Osztály
-
Budapest、ハンガリー、H-1145
- Budapesti Uzsoki Utcai Korhaz
-
Nyíregyháza、ハンガリー、04400
- Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz
-
Pécs、ハンガリー、7624
- Pecsi Tudomanyegyetem Klinikai Kozpont
-
-
-
-
-
Angers、フランス、49055
- Institut de Cancerologie de l Ouest ICO
-
Besançon、フランス、25030
- Hopital Jean Minjoz
-
Bordeaux、フランス、33000
- Institut Bergonie
-
Brest、フランス、29609
- CHRU Brest - Hopital Morvan
-
Clermont-Ferrand、フランス、63011
- Centre Jean Perrin
-
Dijon、フランス、21079
- Centre Georges-François Leclerc
-
Lille、フランス、59000
- Centre Oscar Lambret
-
Lille、フランス、59000
- Hôpital Privé Le Bois
-
Lorient、フランス、56322
- Groupe Hospitalier Bretagne Sud
-
Marseille、フランス、13005
- Hopital de la Timone
-
Montpellier、フランス、34298
- Institut Regional du Cancer de Montpellier Val d'Aurelle
-
Nice、フランス、06189
- Centre Antoine Lacassagne
-
Nîmes、フランス、30029
- Institut de Cancérologie du Gard
-
Paris、フランス、75475
- Hospital Saint-Louis
-
Paris、フランス、75015
- Hopital Europeen Georges-Pompidou
-
Pierre-Bénite、フランス、69495
- Hospices Civils de Lyon HCL
-
Poitiers、フランス、86021
- CHU De Poitiers
-
Rennes、フランス、35062
- Centre Eugene Marquis
-
Ris-Orangis、フランス、91130
- Centre de radiothérapie et d'Oncologie médicale de l'Essonne
-
Saint-Priest-en-Jarez、フランス、42271
- Institut de Cancérologie de Loire
-
Strasbourg、フランス、67098
- Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
-
Toulouse、フランス、31059
- Institut Claudius Regaud
-
Valenciennes、フランス、59300
- Centre Les Dentellieres
-
Villejuif、フランス、94805
- Institut Gustave Roussy
-
-
-
-
-
Barretos、ブラジル、14784-400
- Fundacao Pio XII
-
Belo Horizonte、ブラジル、30130-100
- Universidade Federal De Minas Gerais - Hospital das Clínicas
-
Belo Horizonte、ブラジル、30380-472
- Nucleo de Ensino e Pesquisa do Instituto Mario Penna
-
Curitiba、ブラジル、80530-010
- Instituto de Oncologia do Parana
-
Curitiba、ブラジル、81520 060
- Liga Paranaense de Combate ao Cancer
-
Goiânia、ブラジル、74605-070
- Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge
-
Itajaí、ブラジル、88301-220
- Clínica de Neoplasias Litoral Ltda.
-
Jaú、ブラジル、17210 080
- Fundacao Doutor Amaral Carvalho
-
Natal、ブラジル、59075-740
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre、ブラジル、90035-903
- Hospital das Clinicas de Porto Alegre
-
Porto Alegre、ブラジル、91350 200
- Hospital Nossa Senhora da Conceicao S A
-
Rio de Janeiro、ブラジル、22250 905
- Oncoclinicas Rio de Janeiro S A
-
Rio de Janeiro、ブラジル、20231 050
- Ministerio da Saude Instituto Nacional do Cancer
-
Salvador、ブラジル、41253-190
- Hospital Sao Rafael
-
Santo André、ブラジル、09060-650
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
Sorocaba、ブラジル、18030-005
- Instituto de Oncologia de Sorocaba Onco Clinicas Especializadas
-
São José do Rio Preto、ブラジル、15090-000
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
-
São Paulo、ブラジル、04502-001
- Instituto D Or de Pesquisa e Ensino IDOR
-
São Paulo、ブラジル、01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、ブラジル、05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo、ブラジル、03102-002
- Instituto Brasileiro de Controle do Cancer - Sao Camilo Oncologia
-
São Paulo、ブラジル、01308 050
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes 1
-
-
-
-
-
Pleven、ブルガリア、5800
- UMHAT 'Dr. Georgi Stranski', EAD
-
Plovdiv、ブルガリア、4004
- Complex Oncology Center - Plovdiv EOOD
-
Sofia、ブルガリア、1407
- Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia'
-
Sofia、ブルガリア、1797
- UMHAT Sofia Med
-
Varna、ブルガリア、9010
- Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD
-
-
-
-
-
Aalst、ベルギー、9300
- OLV Ziekenhuis Aalst
-
Antwerp、ベルギー、2020
- ZNA Middelheim
-
Brussels、ベルギー、1200
- Cliniques Universitaires Saint Luc
-
Charleroi、ベルギー、6000
- Clinique Notre Dame de Grâce
-
Ghent、ベルギー、9000
- AZ Maria Middelares
-
Ghent、ベルギー、9000
- UZ Gent
-
Liège、ベルギー、4000
- CHC MontLegia
-
Wilrijk、ベルギー、2610
- Sint-Augustinus AZ
-
Yvoir、ベルギー、5530
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Lisbon、ポルトガル、1400-038
- Champalimaud Foundation Champalimaud Centre
-
Lisbon、ポルトガル、G1R 2J6
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon、ポルトガル、1500-458
- Hospital Lusíadas
-
Lisbon、ポルトガル、1649-035
- H. Santa Maria - Centro Hospitalar de Lisboa Norte
-
Porto、ポルトガル、4200072
- Instituto Portugues de Oncologia
-
-
-
-
-
Bydgoszcz、ポーランド、85 796
- Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
-
Warsaw、ポーランド、02-507
- Centralny Szpital Kliniczny MSWiA w Warszawie
-
Warsaw、ポーランド、02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Wroclaw、ポーランド、50 556
- Uniwersytecki Szpital Kliniczny we Wroclawiu
-
-
-
-
-
Aguascalientes、メキシコ、20230
- Medicos Especialistas en Cancer, S.C.
-
Chihuahua City、メキシコ、31000
- Centro Estatal de Cancerología de Chihuahua
-
Naucalpan、メキシコ、53100
- Oncologia Integral Satelite
-
-
-
-
-
Barnaul、ロシア、656049
- Altai Regional Oncology Dispensary
-
Chelyabinsk、ロシア、454087
- Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine
-
Irkutsk、ロシア、664035
- Irkutsk Regional Oncology Dispensary
-
Ivanovo、ロシア、153040
- Ivanovo Regional Oncology Dispensary
-
Kostroma、ロシア、156005
- Kostroma regional oncology dispensary
-
Kuzmolovsky、ロシア、188663
- Leningrad Regional Oncology Dispensary
-
Moscow、ロシア、105077
- City Clinical Hospital n.a. D.D.Pletnev
-
Moscow、ロシア、117997
- Russian Scientific Center of Roentgenoradiology
-
Moscow、ロシア、119991
- I.M. Sechenov First Moscow State Medical University
-
Moscow、ロシア、125284
- Hertzen Oncology Research Institute
-
Moscow、ロシア、115478
- FSBSI 'N. N. Blokhin Russian Cancer Research Center'
-
Nal'chik、ロシア、360017
- City Clinical Hospital #1
-
Nizhny Novgorod、ロシア、603109
- Privolzhsky District Medical Center under the Federal Medico-Biological Agency
-
Omsk、ロシア、644013
- Clinical Oncology Dispensary
-
Pyatigorsk、ロシア、357502
- GBUZ of Stavropol region Pyatigorsk Oncological Dispensary
-
Saint Petersburg、ロシア、196603
- Private Medical Institution Euromedservice
-
Saint Petersburg、ロシア、197758
- Russian Scientific Center of Radiology and Surgical Technologies
-
Saint Petersburg、ロシア、192148
- LLC 'Strategic Medical Systems'
-
Saint Petersburg、ロシア、195067
- Clinical hopital n/a Petra velikogo
-
Saint Petersburg、ロシア、197022
- Pavlov First Saint Petersburg State Medical University
-
Saint Petersburg、ロシア、197758
- Saint-Petersburg Clinical Scientific And Practical Center For Special Types Of Medical Care
-
Saransk、ロシア、430032
- FGBOU Vo Mordovian National Research State University N. A. N.P. Ogareva
-
Saratov、ロシア、410000
- Saratov State Medical University
-
Smolensk、ロシア、214031
- LLC Uromed
-
Sochi、ロシア、354057
- GBUZ Oncology Centre #2 of Healthcare Department of Krasno
-
Tyumen、ロシア、625041
- Multifunctional clinical medical center 'Medical city'
-
Ufa、ロシア、450000
- Bashkiria State Medical University
-
Vologda、ロシア、160012
- Vologda Regional Oncological Dispensary
-
-
-
-
-
Beijing、中国、100730
- Beijing Hospital
-
Beijing、中国、100730
- Peking Union Medical College Hospital
-
Beijing、中国、100191
- Peking University Third Hospital
-
Beijing、中国、100050
- Beijing Friendship Hospital
-
Beijing、中国、100034
- Peking University First Hospital
-
Beijing、中国、100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
Changchun、中国、130021
- The First Bethune Hospital of Jilin University
-
Chengdu、中国、610041
- Sichuan University Huaxi Hospital
-
Chengdu、中国、610000
- Sichuan Provincial Peoples Hospital
-
Chongqing、中国、400030
- Chongqing University Cancer Hospital
-
Guangzhou、中国、510180
- Guangzhou First Municipal People's Hospital
-
Guangzhou、中国、510120
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
Guangzhou、中国、510060
- Sun Yat Sen University Cancer Center
-
Hangzhou、中国、310014
- Zhejiang Provincial People's Hospital
-
Hangzhou、中国、310020
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Nanchang、中国、330006
- The First Affliated Hospital Of Nanchang University
-
Nanjing、中国、210009
- Jiangsu Cancer Hospital
-
Nanjing、中国、210008
- Nanjing Drum Tower Hospital
-
Shanghai、中国、200127
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
Shanghai、中国、200400
- Huadong Hospital Affiliated to Fudan University
-
Shenyang、中国、110004
- Shengjing Hospital Of China Medical University
-
Shenzhen、中国、518055
- Shenzhen university General Hospital
-
Wenzhou、中国、325000
- First Affiliated Hospital Of Wenzhou Medical College
-
Xi'an、中国、710061
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Kaohsiung City、台湾、807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Niao-Sung Hsiang、台湾、833
- Chang Gung Medical Foundation
-
Taichung、台湾、40447
- China Medical University Hospital
-
Taichung、台湾、40705
- Taichung Veterans General Hospital
-
Tainan、台湾、70403
- National Cheng Kung University Hospital
-
Tainan、台湾、710
- Chi Mei Medical Center Yong Kang
-
Taipei、台湾、10002
- National Taiwan University Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
Taipei、台湾、10449
- Mackay Memorial Hospital
-
Taipei、台湾、11259
- Koo Foundation Sun Yat-Sen Cancer Center
-
Taoyuan、台湾、333
- Chang-Gung Memorial Hospital, LinKou Branch
-
-
-
-
-
Chiba、日本、260-8717
- Chiba Cancer Center
-
Hirosaki、日本、036-8563
- Hirosaki University Hospital
-
Kashiwa、日本、277 8577
- National Cancer Center Hospital East
-
Kita Gun、日本、761 0793
- Kagawa University Hospital
-
Kobe、日本、650-0047
- Kobe City Medical Center General Hospital
-
Koshigaya、日本、343-8555
- Dokkyo Medical University Saitama Medical Center
-
Matsuyama、日本、791-0280
- Aso Co.,Ltd Iizuka Hospital
-
Miyazaki、日本、889-1692
- University of Miyazaki Hospital
-
Nagano、日本、381-8551
- Nagano Municipal Hospital
-
Nagoya、日本、464 8681
- Aichi Cancer Center Hospital
-
Osaka、日本、545 8586
- Osaka City University Hospital
-
Osaka、日本、541 8567
- Osaka International Cancer Institute
-
Sagamihara、日本、252-0375
- Kitasato University Hospital
-
Sakura、日本、285-8741
- Toho University Sakura Medical Center
-
Sapporo、日本、003-0804
- National Hospital Organization Hokkaido Cancer Center
-
Shinjuku-ku、日本、162-8666
- Tokyo Women's Medical University Hospital
-
Tokyo、日本、105-8470
- Toranomon Hospital
-
Tokyo、日本、135 8550
- The Cancer Institute Hospital of JFCR 1
-
Tsukuba、日本、305 8576
- University of Tsukuba Hospital
-
Ube、日本、755-8505
- Yamaguchi University Hospital
-
Yokohama、日本、232 0024
- Yokohama City University Medical Center
-
Ōsaka-sayama、日本、589-8511
- Kindai University Hospital
-
Ōta-ku、日本、373-8550
- Gunma Prefectural Cancer Center
-
-
-
-
-
Busan、韓国、49241
- Pusan National University Hospital
-
Daejeon、韓国、35015
- Chungnam National University Hospital
-
Goyang-si、韓国、410-769
- National Cancer Center
-
Gwangju、韓国、61469
- Chonnam National University Hospital
-
Gyeonggi-do、韓国、13620
- Seoul National University Bundang Hospital
-
Incheon、韓国、21565
- Gachon University Gil Medical Center
-
Seoul、韓国、03080
- Seoul National University Hospital
-
Seoul、韓国、03722
- Severance Hospital Yonsei University Health System
-
Seoul、韓国、03181
- Kangbuk Samsung Hospital
-
Seoul、韓国、02841
- Korea University Anam Hospital
-
Seoul、韓国、135-710
- Samsung Medical Center
-
Wŏnju、韓国、26426
- Yonsei University Wonju Severance Christian Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologic demonstration of transitional cell carcinoma of the urothelium. Minor components ( less than [<] 50 percent [%] overall) of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
- Metastatic or surgically unresectable urothelial cancer
- Documented progression of disease, defined as any progression that requires a change in treatment, prior to randomization
- Cohort 1: Prior treatment with an anti-PD-(L) 1 agent as monotherapy or as combination therapy; no more than 2 prior lines of systemic treatment. Cohort 2: No prior treatment with an anti-PD-(L) 1 agent; only 1 line of prior systemic treatment. Subjects who received neoadjuvant or adjuvant chemotherapy and showed disease progression within 12 months of the last dose are considered to have received systemic therapy in the metastatic setting.
- A woman of childbearing potential who is sexually active must have a negative pregnancy test (beta human chorionic gonadotropin [beta hCG]) at Screening (urine or serum)
- Participants must meet appropriate molecular eligibility criteria
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
- Adequate bone marrow, liver, and renal function
Exclusion Criteria:
- Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to randomization
- Active malignancies (that is, requiring treatment change in the last 24 months). The only allowed exceptions are: urothelial cancer, skin cancer treated within the last 24 months that is considered completely cured, localized prostate cancer with a gleason score of 6 (treated within the last 24 months or untreated and under surveillance) and localized prostate cancer with a gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence.
- Symptomatic central nervous system metastases
- Received prior fibroblast growth factor receptor (FGFR) inhibitor treatment
- Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
- Current central serous retinopathy (CSR) or retinal pigment epithelial detachment of any grade.
- History of uncontrolled cardiovascular disease
- Impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Cohort 1 (Arm 1A): Erdafitinib
Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]). Participants who enter in Long-term extension (LTE) phase will continue to receive the erdafitinib tablet as per investigator's decision. |
Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
他の名前:
FGFRi CTA will be used to determine molecular eligibility. |
|
実験的:Cohort 1 (Arm 1B): Vinflunine or Docetaxel
Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-[L] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive Vinflunine or Docetaxel until the participant can commercially receive chemotherapy within the local healthcare system. |
FGFRi CTA will be used to determine molecular eligibility. Participants will receive vinflunine 320 mg/m^2 as a 20-minute intravenous infusion. Participants will receive docetaxel 75 mg/m^2 as a 1 hour intravenous infusion. |
|
実験的:Cohort 2 (Arm 2A): Erdafitinib
Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs). Participants who enter in LTE phase will continue to receive the erdafitinib tablet as per investigator's decision. |
Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
他の名前:
FGFRi CTA will be used to determine molecular eligibility. |
|
実験的:Cohort 2 (Arm 2B): Pembrolizumab
Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive the pembrolizumab until 2 years after the first dose of pembrolizumab (at start of study) or until the participant can commercially receive pembrolizumab within the local healthcare system, whichever comes first. |
FGFRi CTA will be used to determine molecular eligibility. Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)
|
Overall survival was measured from the date of randomization to the date of the participant's death. |
From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
時間枠:From randomization (3 days prior to Cycle 1 Day 1) until disease progression or relapse from CR or death (maximum up to 51.7 months)
|
PFS was defined as the time from the date of randomization to the date of disease progression or relapse from complete response (CR) based on investigator assessment using RECIST v 1.1, or death due to any cause, whichever occurred first. As per RECIST v 1.1, CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to less than (<) 10 millimeters (mm). Progressive disease (PD) was defined as at least 20 percent (%) increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of greater than or equal to (>=) 5 mm or appearance of at least 1 new lesion. |
From randomization (3 days prior to Cycle 1 Day 1) until disease progression or relapse from CR or death (maximum up to 51.7 months)
|
|
Objective Response Rate (ORR) Per RECIST Version 1.1
時間枠:From start of the treatment (Day 1 Cycle 1) up to maximum of 51.7 months
|
ORR was defined as the percentage of participants who achieved CR or partial response (PR) as determined by investigator per RECIST v1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
From start of the treatment (Day 1 Cycle 1) up to maximum of 51.7 months
|
|
Change From Baseline in Physical Functioning Scales of the Functional Assessment of Cancer Therapy - Bladder Cancer (FACT-Bl)
時間枠:Baseline up to Cycle 11 (each cycle was of 21 days)
|
The FACT-Bl consisted of 39 items, with 5-point Likert scales, covering 5 primary domains: physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns for participants with bladder cancer. The response options ranged from 0 to 4 where, 0='Not at all" and 4= "very much." FACT-Bl total score ranged from 0 (worst) to 156 (best). The higher the score, the better the quality of life (QOL). The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline up to Cycle 11 (each cycle was of 21 days)
|
|
Time Until Symptom Deterioration
時間枠:Randomization (3 days prior to Cycle 1 Day 1) up to maximum of 51.7 months
|
Time until symptom deterioration was defined as the first time to increase in urinary bladder cancer symptoms score from the day of randomization beyond a meaningful change threshold compared to baseline. The urinary bladder cancer symptom score was subset of FACT-Bl which included 3 items related to urinary symptoms, 5-point Likert scale. Response options ranged from 0 to 4, 0 = Not at all, 1= A little bit, 2= Somewhat, 3=Quite a bit, 4 = Very much. A response of 0 indicated no symptoms and 4 indicated severe symptoms. Total sum scores ranged from 0 to 12, higher scores indicate relatively poor quality of life. |
Randomization (3 days prior to Cycle 1 Day 1) up to maximum of 51.7 months
|
|
Percentage of Participants With Shift From Baseline in Patient-Global Impression of Severity (PGIS)
時間枠:Baseline, 51.7 months
|
The PGI-S was a single item patient-reported measure assessing participants' impression of severity in bladder cancer symptoms. It uses a 4-point Likert scale as follows: symptoms are: 0-"absent (no symptoms)", 1-"mild", 2-"moderate", 3="severe" and 4= "very severe". Percentage of participants with shift from baseline in PGIS score were reported. A negative shift from baseline in PGIS score indicated Improvement and positive shift from baseline in PGIS score indicated Worsening. The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline, 51.7 months
|
|
Change From Baseline in Utility Scale of the European Quality of Life-5 Dimensions-5 Levels Questionnaire (EQ-5D-5L)
時間枠:Baseline up to Cycle 11 (each cycle was of 21 days)
|
The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L was a 5-item questionnaire that assessed 5 domains included mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Health utility values generated from the EQ-5D generally range from 0 (a state as bad as being dead) to 1 (full health), with higher scores indicating better QoL. The EQ visual analog scale (VAS) recorded the patient's self-rated health on a VAS, ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better QoL. The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline up to Cycle 11 (each cycle was of 21 days)
|
|
Change From Baseline in Visual Analog Scale (VAS) of the European Quality of Life-5 Dimensions-5 Levels Questionnaire (EQ-5D-5L)
時間枠:Baseline up to Cycle 11 (each cycle was of 21 days)
|
The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L was a 5-item questionnaire that assessed 5 domains included mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Health utility values generated from the EQ-5D generally range from 0 (a state as bad as being dead) to 1 (full health), with higher scores indicating better QoL. The EQ VAS recorded the patient's self-rated health on a VAS, ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better QoL. The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline up to Cycle 11 (each cycle was of 21 days)
|
|
Duration of Response (DOR) as Per RECIST Version 1.1
時間枠:From date of first documented response to date of first documented PD or death whichever occurred first (maximum up to 51.7 months)
|
DOR was defined as time from the date of initial documentation of an overall response (CR or PR) to the date of first documented evidence of progressive disease (PD) (or relapse for participants who experience CR) or death. As per RECIST Version 1.1: CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of >=5 mm or appearance of at least 1 new lesion. |
From date of first documented response to date of first documented PD or death whichever occurred first (maximum up to 51.7 months)
|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
時間枠:From start of the treatment (Day 1 Cycle 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (maximum up to 51.7 months)
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were the events between first dose of study drug and up to 30 days after last dose or before start of new anticancer therapy, whichever occurred first. All TEAEs including serious and non-serious events were reported in this outcome measure. |
From start of the treatment (Day 1 Cycle 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (maximum up to 51.7 months)
|
|
Number of Participants With Shift From Baseline Grade Less Than or Equal to (<=) 2 to Grade Greater Than or Equal to (>=) 3 Post-Baseline in Laboratory Parameter: Hematology
時間枠:From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
Hematology parameters included: hemoglobin, platelet count, white blood cell (WBC) count, and absolute neutrophil count (ANC). According to national cancer institute (NCI)-common terminology criteria for adverse events (CTCAE) version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE and Grade 0= normal. In this outcome measure number of participants with shifts from baseline (BL) Grade <= 2 to Grade >=3 post-baseline in any of hematology parameters are reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only those categories in which at least one participant had data were reported in this outcome measure. |
From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
|
Number of Participants With Shift From Baseline Grade <= 2 to Grade >=3 Post-Baseline in Laboratory Parameter: Chemistry
時間枠:From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
Chemistry parameters included: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, chloride, creatinine, bicarbonate, corrected calcium, magnesium, potassium, sodium, serum phosphate, serum parathyroid hormone. According to NCI-CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE and Grade 0= normal. In this outcome measure number of participants with shifts from baseline (BL) Grade <= 2 to Grade >=3 post-baseline in any of chemistry parameters are reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only those categories in which at least one participant had data were reported in this outcome measure. |
From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
|
Number of Participants With Abnormalities in Electrocardiograms (ECG) Parameters
時間枠:Day 1 of Cycle 2 and 4 (Each Cycle 21 days)
|
Number of participants with abnormalities in ECG parameters were reported. The ECG variables included heart rate, RR interval, PR interval, QRS interval, QT interval and QT corrected according to Fridericia's formula (QTcF). ECG abnormality criteria include: Heart rate: Low <50 beats per minute (bpm); High > 100 bpm, RR interval: Low < 600 milliseconds (ms); High > 1000 ms, QT interval: High > 500 ms, QTc interval: High > (450 ms for males, 470 ms for females); increase to >500 ms. |
Day 1 of Cycle 2 and 4 (Each Cycle 21 days)
|
|
Change From Baseline in Vital Signs: Weight
時間枠:Baseline, 51.7 months
|
Changes from baseline in vital signs (weight) was reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. |
Baseline, 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Amsler Grid Test
時間枠:From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in Amsler grid test was reported. Baseline and post-baseline visit findings included normal, abnormal CS (clinically significant) and abnormal NCS (not clinically significant). Clinical significance was determined by investigator's assessment. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Visual Acuity
時間枠:From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in visual acuity (VA) was reported. Worst post-baseline was defined as the visual acuity value that resulted in the largest change from baseline value for either eye. Baseline value was considered for the eye that reported the worst-post baseline value. Baseline and post-baseline visit visual acuity findings included: <= 20/30, >20/30 to <= 20/40, >20/40 to <= 20/80, >20/80 to <= 20/120, >20/120 to <= 20/160, >20/160 to <= 20/200, >20/200. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening in visual acuity from baseline value to worst post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Optical Coherence Tomography: Subretinal Fluid
時間枠:From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in optical coherence tomography for subretinal fluid was reported. At the baseline visit, findings may have been absent or present/visible. At all post-baseline visits, findings were compared to baseline and results may have been increased, decreased, stable or resolved. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only category (shift from absent at baseline to increased at post-baseline) in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Optical Coherence Tomography: Retinal Pigment Epithelium (RPE) Elevation
時間枠:From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in optical coherence tomography for RPE elevation was reported. At the baseline visit, findings may have been absent or present/visible. At all post-baseline visits, findings were compared to baseline and results may have been increased, decreased, stable or resolved. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Slit Lamp Biomicroscopy: Retinal Assessment
時間枠:From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in slit lamp biomicroscopy examination for retinal assessment was reported. Baseline and post-baseline visit findings included normal, abnormal CS and abnormal NCS. Clinical significance was determined by investigator's assessment. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Oral Clearance (CL/F) of Erdafitinib
時間枠:Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle was of 21 days)
|
Clearance was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. |
Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle was of 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) of Erdafitinib
時間枠:Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle is of 21 days)
|
Area under the plasma concentration time-curve from time zero to the time t (AUC[0-t]) was reported. |
Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle is of 21 days)
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CR108401
- 2017-002932-18 (EudraCT番号)
- 42756493BLC3001 (その他の識別子:Janssen Research & Development, LLC)
- 2017 (米国 NIH グラント/契約)
- 2023-510296-56-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。